GEORGETOWN, Texas, March 22, 2021 /PRNewswire-PRWeb/ — Gilad&Gilad, a health science company with core competency in neuroscience, announced today that it is relocating its offices to Georgetown (Austin area), Texas. The move is an important step for the Company’s further investment in the development and marketing of its G-Agmatine®-based products. “We are relocating to Austin because of new business connections and proximity to good medical centers. The move will facilitate marketing of our signature products, AgmaSet® and AgmaVet®, which are superior for supporting proper nerve functions in humans and animals, respectively”, said Dr. Gad M. Gilad, CEO of Gilad&Gilad. “The move will also enable clinical studies aimed at substantiating the effectiveness of novel G-Agmatine®-based products in supporting additional bodily functions.
These options were not readily available in the Las Vegas area. And as a bonus, the climate is better in Austin“. Added Gilad.
Gilad&Gilad continues to maintain its contract manufacturing in South California. “We can assure our customers that the highest quality they expect of our products will be absolutely maintained.” indicated Gilad.
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
About Gilad&Gilad LLC
Gilad&Gilad is a health science company with core competency in Neuroscience. The company has developed the exclusive Agmaceuticals(TM) line of products based on the breakthrough discovery of the neuroprotective properties agmatine. AgmaSet® (a dietary supplement) and AgmaVet® (for animals) are the first-of-their-kind nutraceuticals containing G-Agmatine® (the best brand of agmatine), with superior effectiveness for healthy nerve functions. The Company builds its reputation by continuous investment in scientific research and clinical studies. – For further information, visit https://ForNerveHealth.com.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Media Contact
GAD M. GILAD, PhD, Gilad&Gilad LLC, +1 3235990774, gmgilad@gmail.com
SOURCE Gilad&Gilad
MEMPHIS, Tenn., July 5, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare announced its four Memphis-based adult hospitals…
TEMPE, Ariz., July 5, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in June…
mCare Digital unveils the mCareWatch MW-241 powered by KORE connectivity ATLANTA, July 5, 2024 /PRNewswire/…
Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of…
Image acquisition and defocusing correction techniques enable observations of atomic-scale magnetic fields at never-before-seen resolution…
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…